← Back to Search

Other

VX-548 for Acute Pain

Phase 3
Waitlist Available
Research Sponsored by Vertex Pharmaceuticals Incorporated
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
Pivotal Trial

Summary

This trial is testing VX-548, a new medication, to see if it can help reduce pain in patients who have had abdominoplasty surgery. VX-548 likely works by blocking pain signals in the body.

Eligible Conditions
  • Acute Pain

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

3Treatment groups
Experimental Treatment
Active Control
Placebo Group
Group I: VX-548Experimental Treatment2 Interventions
Participants will receive VX-548.
Group II: Hydrocodone bitartrate/acetaminophen (HB/APAP)Active Control2 Interventions
Participants will receive HB/APAP.
Group III: PlaceboPlacebo Group2 Interventions
Participants will receive placebos matched to VX-548 and HB/APAP.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Placebo (matched to HB/APAP)
2021
Completed Phase 3
~2770
VX-548
2022
Completed Phase 3
~3790

Find a Location

Who is running the clinical trial?

Vertex Pharmaceuticals IncorporatedLead Sponsor
255 Previous Clinical Trials
33,567 Total Patients Enrolled
8 Trials studying Acute Pain
2,858 Patients Enrolled for Acute Pain

Media Library

VX-548 (Other) Clinical Trial Eligibility Overview. Trial Name: NCT05558410 — Phase 3
Acute Pain Research Study Groups: VX-548, Hydrocodone bitartrate/acetaminophen (HB/APAP), Placebo
Acute Pain Clinical Trial 2023: VX-548 Highlights & Side Effects. Trial Name: NCT05558410 — Phase 3
VX-548 (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05558410 — Phase 3
~363 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top